TY - JOUR
T1 - Relationship between lung function impairment and health-related quality of life in COPD and interstitial lung disease
AU - Berry, Cristine E.
AU - Drummond, M. Bradley
AU - Han, Mei Lan K.
AU - Li, Daner
AU - Fuller, Cathy
AU - Limper, Andrew H.
AU - Martinez, Fernando J.
AU - Schwarz, Marvin I.
AU - Sciurba, Frank C.
AU - Wise, Robert A.
N1 - Funding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Han has performed speaking for Boehringer Ingelheim GmbH; Pfizer, Inc; and GlaxoSmithKline. She has also consulted for Novartis AG; Genentech, Inc; GlaxoSmithKline; Pfizer, Inc; Boehringer Ingelheim GmbH; and MedImmune LLC. Dr Martinez has participated in advisory boards in COPD development for GlaxoSmithKline; MedImmune LLC; AstraZeneca; Merck & Co, Inc; Perl; Novartis AG; Forest Laboratories, Inc/Almirall, SA; Takeda Pharmaceuticals International GmbH; Schering-Plough Corp; Hoffmann-La Roche Inc; Bayer; Actelion Pharmaceuticals Ltd; Pfizer, Inc; Talecris; Health Learning Systems; Comgenix; FBCommunications; BoomComm; and Ikaria, Inc. He has been a member of a steering committee for COPD studies sponsored by GlaxoSmithKline, Actelion Pharmaceuticals Ltd, MPex, and Takeda Pharmaceuticals International GmbH. He has participated in US Food and Drug Administration mock panels for Boehringer Ingelheim GmbH and Forest Laboratories, Inc. He has been a member of advisory boards for IPF drug development for Elan Corp, plc; Quark; Genzyme Corp; Takeda Pharmaceuticals International GmbH; and Ikaria, Inc. He has been a member of steering committees for IPF studies sponsored by Actelion Pharmaceuticals, Ltd; Genzyme Corp; Gilead; and Johnson & Johnson/Janssen Biotech, Inc. The University of Michigan received funds from Boehringer Ingelheim GmbH for COPD study and from Actelion Pharmaceuticals Ltd for IPF study. Dr Martinez has served on speaker's bureaus or in continuing medical education activities sponsored by GlaxoSmithKline; NACE; Med-Ed; Potomac; Pfizer, Inc; Boehringer Ingelheim GmbH; Schering-Plough Corp; Vox Medica, Inc; American Lung Association; WebMD; Epocrates; AstraZeneca; France Foundation; Altana Pharma/Nycomed; and UpToDate. He has received royalties from Associates in Medical Marketing and Castle Connolly. Dr Sciurba has received research funds from the National Institutes of Health; GlaxoSmithKline; Pfizer, Inc; Boehringer Ingelheim GmbH; and Forest Laboratories, Inc. He has also received consulting funds from GlaxoSmithKline, AstraZeneca, and PneumRx. Dr Wise has served as a consultant for AstraZeneca; Boehringer Ingelheim GmbH; GlaxoSmithKline; InterMune; Merck & Co, Inc; MedImmune LLC; Novartis AG; Pfizer, Inc; Sunovion Pharmaceuticals, Inc; and Spiration, Inc. He has received research grants from Boehringer-Ingelheim GmbH; Forest Laboratories, Inc; and GlaxoSmithKline. Drs Berry, Drummond, Limper, and Schwarz and Mss Li and Fuller have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Funding Information:
Role of sponsors: The National Heart, Lung and Blood Institute Lung Tissue Research Consortium (LTRC) provided the data for this study. This publication was made possible by Grant 1KL2RR025006-01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.
PY - 2012/9
Y1 - 2012/9
N2 - Background: Health-related quality-of-life (HRQL) measures have been correlated with lung function in patients with COPD and interstitial lung disease (ILD). However, different pathophysiologic mechanisms may influence how these distinct diseases affect HRQL, resulting in differing HRQL by pulmonary diagnosis among patients with similar severity of ventilatory impairment. Methods: The National Heart, Lung, and Blood Institute Lung Tissue Research Consortium provided data on well-characterized participants with COPD (n = 576) and ILD (n = 405) at four clinical sites. Using multiple linear regression, we examined the effects of FEV1 (% predicted) and diagnosis (ILD vs COPD) on HRQL scores, including total St. George Respiratory Questionnaire (SGRQ) scores and Short Form-12 (SF-12) physical component summary (PCS) and mental component summary (MCS) scores. Results: Participants with ILD had, on average, higher SGRQ scores (15.33 points; 95% CI, 12.46-18.19; P <.001) and lower SF-12 PCS scores (-4.73 points;95% CI, -6.31 to -3.14; P <.001) compared with patients with COPD with similar FEV1 % predicted values, indicating worse HRQL. The specific diagnosis also modified the effect of FEV1 on the total SGRQ score (P =.003) and the SF-12 PCS score (P =.03). There was no relationship between lung function and SF-12 MCS scores. Conclusions: HRQL scores were worse for patients with ILD compared with patients with COPD with similar degrees of ventilatory impairment. Differences in dyspnea mechanism or in the rate of disease progression may account for these differences in HRQL.
AB - Background: Health-related quality-of-life (HRQL) measures have been correlated with lung function in patients with COPD and interstitial lung disease (ILD). However, different pathophysiologic mechanisms may influence how these distinct diseases affect HRQL, resulting in differing HRQL by pulmonary diagnosis among patients with similar severity of ventilatory impairment. Methods: The National Heart, Lung, and Blood Institute Lung Tissue Research Consortium provided data on well-characterized participants with COPD (n = 576) and ILD (n = 405) at four clinical sites. Using multiple linear regression, we examined the effects of FEV1 (% predicted) and diagnosis (ILD vs COPD) on HRQL scores, including total St. George Respiratory Questionnaire (SGRQ) scores and Short Form-12 (SF-12) physical component summary (PCS) and mental component summary (MCS) scores. Results: Participants with ILD had, on average, higher SGRQ scores (15.33 points; 95% CI, 12.46-18.19; P <.001) and lower SF-12 PCS scores (-4.73 points;95% CI, -6.31 to -3.14; P <.001) compared with patients with COPD with similar FEV1 % predicted values, indicating worse HRQL. The specific diagnosis also modified the effect of FEV1 on the total SGRQ score (P =.003) and the SF-12 PCS score (P =.03). There was no relationship between lung function and SF-12 MCS scores. Conclusions: HRQL scores were worse for patients with ILD compared with patients with COPD with similar degrees of ventilatory impairment. Differences in dyspnea mechanism or in the rate of disease progression may account for these differences in HRQL.
UR - http://www.scopus.com/inward/record.url?scp=84865849080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865849080&partnerID=8YFLogxK
U2 - 10.1378/chest.11-1332
DO - 10.1378/chest.11-1332
M3 - Article
C2 - 22576634
AN - SCOPUS:84865849080
SN - 0012-3692
VL - 142
SP - 704
EP - 711
JO - Chest
JF - Chest
IS - 3
ER -